AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Massachusetts Biotech Firm Expects Human Trials for Anti-cancer Protein.
Knight Ridder/Tribune Business News
Sep. 17 -- A potent new cancer-fighting protein discovered in the Boston lab of Dr. Judah Folkman can be made by slightly altering a drug that's already on the market, and therefore could enter human trials as early as next year, say officials of a Framingham biotech firm.
The new protein seems to be at least as powerful as endostatin, the widely publicized tumor-starving drug also discovered in Folkman's lab. Endostatin is about to enter its first, long-awaited human tests in Boston.
Called antiangiogenic antithrombin, or aaAT, the new protein is being described publicly for the first time today, in the current issue of the journal Science.
Genzyme Molecular Oncology in Framingham, which has licensed ...
- Baxter to distribute treatment for antithrombin III deficiency in U.S. (Baxter...
- Press release article from: PR Newswire June 19, 1990 700+ words
...BAXTER TO DISTRIBUTE TREATMENT FOR ANTITHROMBIN III DEFICIENCY IN U.S. GLENDALE, Calif...Kabi Vitrum AB to distribute ATnativ Antithrombin III (Human) Heat treated, in the United...treatment of patients with hereditary antithrombin III deficiency in connection with surgical...
- JAPAN GOVT TENDER - ANTITHROMBIN III.
- News wire article from: AsiaPulse News September 22, 2000 700+ words
...Asia Pulse Tender *** KYOTO UNIVERSITY TO PROCURE ANTITHROMBIN III The following is a procurement notice published in the...products to be purchased: Freeze-dried Concentrated Human Antithrombin III, Neuart or its equivalent (500 units (with solvent...
- Heparin cofactor II, antithrombin III have separate localization in skin wounds.
- Newspaper article from: Medical Devices & Surgical Technology Week December 14, 2003 700+ words
...com & NewsRx.net) -- Heparin cofactor II, antithrombin III are serpins with separate localization in acute and healing...Immunology, Wound Healing, Serpins, Heparin Cofactor II, Antithrombin III, Proteomics, Histology, and Wound Care. This article...
- Genzyme Transgenics Receives United States Patent for Transgenic Production of...
- Press release article from: PR Newswire December 1, 1998 700+ words
...granted U.S. Patent 5,843,705, "Transgenically Produced Antithrombin III" by the United States Patent and Trademark Office. The patent covers recombinant human antithrombin III (rh AT III) produced in the milk of transgenic goats. Currently...
- Recombinant human antithrombin III study results reported at scientific meeting.
- Newspaper article from: Biotech Week October 23, 2002 700+ words
...GTC Biotherapeutics, Inc., announced that the results from its pharmacokinetic (PK) study of recombinant human antithrombin III (rhATIII) in patients with a hereditary deficiency (HD) of antithrombin were presented at the British Society for Haemostasis...
- Recombinant human antithrombin III study results reported at scientific...
- Newspaper article from: Health & Medicine Week October 21, 2002 700+ words
...GTC Biotherapeutics, Inc., announced that the results from its pharmacokinetic (PK) study of recombinant human antithrombin III (rhATIII) in patients with a hereditary deficiency (HD) of antithrombin were presented at the British Society for Haemostasis...
- rhATIII PK study completed.(recombinant human antithrombin III...
- Newspaper article from: Proteomics Weekly August 26, 2002 700+ words
...Biotherapeutics, Inc., (GTC) has completed data gathering and analysis in the pharmacokinetic study of recombinant human antithrombin III (rhATIII) in patients with a hereditary deficiency of the antithrombin blood protein. In accordance with good scientific...
- GTC Biotherapeutics Completes Enrollment in European Efficacy Study;...
- Press release article from: PR Newswire December 17, 2003 700+ words
...Biotherapeutics, Inc. (Nasdaq: GTCB; "GTC") announced today that enrollment into the efficacy study for recombinant human antithrombin III (rhATIII) has been completed. The results of the efficacy study will be included in a filing requesting marketing authorization...